Citius Pharmaceuticals, Inc. - Director's Dealing 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2021-07-22

Reporting Person: Webb Carol (Director)

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-22	Options to Purchase Common Stock	$2.00	A	15000	Acquired	2031-07-22	Common Stock (15000)	Direct

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Common Stock	$1.69	2031-02-16	Common Stock (25000)	25000	Direct
Options to Purchase Common Stock	$1.01	2030-10-06	Common Stock (35000)	35000	Direct
Options to Purchase Common Stock	$1.39	2030-07-07	Common Stock (25000)	25000	Direct
Options to Purchase Common Stock	$0.67	2029-10-08	Common Stock (25000)	25000	Direct
Options to Purchase Common Stock	$1.62	2028-09-04	Common Stock (15000)	15000	Direct
Options to Purchase Common Stock	$3.45	2027-09-13	Common Stock (10000)	10000	Direct
Options to Purchase Common Stock	$0.015	2024-03-17	Common Stock (12071)	12071	Direct
Options to Purchase Common Stock	$12	2026-06-23	Common Stock (13334)	13334	Direct

F1: The options will vest in full on July 22, 2022.

F2: The options will vest in full on February 16, 2022.

F3: The options will vest in full on October 6, 2021.

F4: The options will vest in full on July 7, 2021.

F5: The options will vest in full on October 8, 2020.

F6: The options vest in full on September 4, 2019.

F7: The options vest in full on September 13, 2018.

F8: The options vested in 1/3 increments over a three-year period with the first installment vesting on March 17, 2015.

F9: The options vested in full on the first anniversary of the date of grant.